Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC By Ogkologos - November 8, 2024 639 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-522 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... March 1, 2024 Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas July 10, 2023 Atlantic rowing trio smash world record and raise thousands for cancer... January 24, 2022 Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients... November 21, 2020 Load more HOT NEWS How TRACERx is helping us predict lung cancer’s next move Survivor Sees Mom Fighting Breast Cancer At Brunch And Pays For... DIY Mosquito Traps & Deterrents (That Really Work) FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer
